Wang Li, Ma De-Xun, Liu Shu-Feng, Gao Chun-Ji
Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.Department of Hematology, Laoshan Branch of No. 971 Hospital of Chinese PLA, Qingdao 266101, Shandong Province, China.
Department of Hematology, Laoshan Branch of No. 971 Hospital of Chinese PLA, Qingdao 266101, Shandong Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Feb;27(1):283-287. doi: 10.7534/j.issn.1009-2137.2019.01.046.
Graft-versus-host disease (GVHD) is a frequently encountered serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), it limits the success and widespread use of allo-HSCT. Mesenchymal stem cells (MSCs) are selected as ideal prophylactic and treatment means for GVHD during allo-HSCT due to their unique immunomodulatory and regenerative properties. Herein, the recent research progress about the prevantive and therapeutic effects of MSCs on GVHD and several issues related with the applications of MSC, including whether MSCs increasing risk of primary disease relapse and infection, impact of several clinical parameters on the clinical response to MSCs, and the prevantive and therapeutic effect of MSC-derived extracellular vesicles on GVHD are systematically reviewed.
移植物抗宿主病（GVHD）是异基因造血干细胞移植（allo-HSCT）后常见的严重并发症，限制了allo-HSCT的成功及广泛应用。间充质干细胞（MSCs）因其独特的免疫调节和再生特性，被选为allo-HSCT期间预防和治疗GVHD的理想手段。本文系统综述了MSCs对GVHD预防和治疗作用的最新研究进展，以及与MSCs应用相关的几个问题，包括MSCs是否增加原发性疾病复发和感染风险、几个临床参数对MSCs临床反应的影响，以及MSCs来源的细胞外囊泡对GVHD的预防和治疗作用。
